Eine Frage eines Unwissenden... habe gestern in Berlin (über Spk) ein paar Viragen gekauft.. kann ich die nur in Deutschland verkaufen, oder auch an der Amex? Hier wird von 0,60 gesprochen, die ich in D nicht sehe... Help
Anzeige
Meldung des Tages: Warum Kupfer und Silber aus Nevada plötzlich wieder im Fokus stehen könnten
Neuester,
zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum Übersicht Alle
Zurück
Weiter
1 2 3 4 5 6
Antworten | Hot-Stocks-Forum Übersicht Alle
Zurück
Weiter 1 2 3 4 5 6
wer möchte auf Geld verdien verzichten
Beiträge:
142
Zugriffe: 12.467 / Heute: 4
Zugriffe: 12.467 / Heute: 4
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
ich hab meine noch, die ich zu 0,36 gekauft habe, warten wir mal ab...
Was ist mit Hartcourt los, die stürzt ja nur noch!
Was ist mit Hartcourt los, die stürzt ja nur noch!
...aber wenn die kommt, dann aber richtig...
Dinger dann wieder zu 0,35 abgestossen. Spekuliere darauf heute zu Beginn wieder um die 0,27-0,30 reinzukommen...
We will see! Mittelfristig sehe ich auch grosse Chancen, wobei der Wert auch sehr schnell wieder drehen kann...
Fundamental sieht es ja schon eher düster aus. Hier treibt lediglich die "SARS" Phantasie. Bei Multexinvestor bekommt "Viragen" eine 1 bei einer Skala von 10.
1 ist die höchste Risikostufe (very high risk)...
Das Spielchen geht jedenfalls weiter! Viel Glück!
We will see! Mittelfristig sehe ich auch grosse Chancen, wobei der Wert auch sehr schnell wieder drehen kann...
Fundamental sieht es ja schon eher düster aus. Hier treibt lediglich die "SARS" Phantasie. Bei Multexinvestor bekommt "Viragen" eine 1 bei einer Skala von 10.
1 ist die höchste Risikostufe (very high risk)...
Das Spielchen geht jedenfalls weiter! Viel Glück!
Ich möchte die Euphorie bei Viragen ein wenig bremsen.
Von der Patenterteilung bis zur medikamentären Nutzung kann noch sehr viel Zeit vergehen!
Bis dahin ist SARS möglicherweise schon Geschichte!
Dennoch kann man das Moment von Viragen für gewinnbringende Trades ausnützen!
QADSAN
Von der Patenterteilung bis zur medikamentären Nutzung kann noch sehr viel Zeit vergehen!
Bis dahin ist SARS möglicherweise schon Geschichte!
Dennoch kann man das Moment von Viragen für gewinnbringende Trades ausnützen!
QADSAN
wie wirds nächste Woche wohl in Sachen Viragen weitergehen?
Viragen Signs Drug Distribution Agreement for Hong Kong
PLANTATION, FLORIDA – May 22, 2003 – Viragen, Inc. (AMEX: “VRA”) and Viragen International, Inc. (OTC BB: “VGNI”) today announced that the Companies have entered into an exclusive distribution agreement with CJ Pharma, U.S. Pharmaceutical Division of CJ Corporation, and the CJ Hong Kong Ltd. subsidiary, as exclusive distributors of natural interferon in Hong Kong. Viragen’s human leukocyte-derived alpha interferon is currently approved in Hong Kong as a second-line therapy for the treatment of patients with Hairy Cell Leukemia (HCL) or Chronic Myelogenous Leukemia (CML) who did not respond to recombinant (synthetic) interferon regimens.
CJ Corporation (formerly Cheil Jedang) was established as the first manufacturing operation unit of the Samsung Group in 1953. Now a split-off of Samsung Group, the CJ Group recorded over $6 billion in revenues last year, conducting business with over 60 different countries through its thirty-two offices around the world.
“We are very pleased to build upon our relationship with a proven leader such as CJ Pharma,” stated Viragen’s Executive Vice President, Mel Rothberg. “We have been working very closely with CJ to commercialize our natural interferon in previously assigned territories in Latin America. Now we are expanding our work together to include the introduction of the drug into the Hong Kong market.”
CJ Pharma exclusively represents Viragen’s products in the following territories: Brazil, Chile, Uruguay, Peru, Costa Rica, Honduras, Nicaragua, Guatemala, Panama and Hong Kong. CJ Pharma is responsible for all costs associated with the regulatory approval process, including clinical trials if required, in each of the respective countries.
CJ Hong Kong’s General Manager, Mr. Jong Hwan Park, stated, “We are excited to attain the rights to distribute such a potent anti-viral product with Viragen’s multi-subtype human interferon. Our immediate priority is to expand the indications for which the product is currently approved to include a broad range of viral and malignant diseases and we are proceeding with the regulatory registration process.”
Dr. Andrew Gorman, Vice President, CJ Pharma (Princeton, NJ), stated “We believe that natural interferon represents a very attractive international market opportunity for us and our commitment to Viragen now extends from South America to Asia. Our foremost priority is to offer products that promote better health for everyone and this immune-enhancing drug offers that kind of promise in treating a variety of diseases.”
Backgrounder:
The majority of alpha interferons that are marketed are single-subtype recombinant interferons. Therapy resistance is not unusual with recombinant interferons with a significant percentage of patients failing to respond to standard therapy. In some instances, recombinant interferon is rejected by the patient’s immune system, usually caused by the formation of neutralizing antibodies which may lead to a loss of clinical efficacy. Also, many patients cannot tolerate the adverse side-effects sometimes associated with recombinant therapy. High doses of recombinant interferon may cause serious, even life-threatening side effects.
The Natural Choice
Viragen believes that in many cases, especially when higher dosages are required, its natural interferon appears to offer substantial advantages to recombinant interferon regimens:
Natural interferon is very similar to interferon secreted by the human immune system during a normal virus infection, significantly lowering the risk of the drug being rejected.
Natural interferon contains the multiple subtype composition that is characteristic of interferon produced by the human body. It is believed that this may result in a broader spectrum of anti-viral activity with each subtype perhaps showing a specific biological activity.
Natural interferon does not appear to cause the formation of neutralizing antibodies.
Natural interferon is significantly less immunogenic than recombinant interferon. It should be far better tolerated by patients with fewer side effects and thus allow for higher doses to be administered to maximize the benefits of the therapy.
About CJ Corporation:
CJ Corporation (formerly Cheil Jedang) was established as the first manufacturing operation unit of the Samsung Group in 1953. The CJ Group recorded over $6 billion in revenues last year, conducting business with over 60 different countries through its thirty-two offices around the world. CJ Pharma is the pharmaceutical division in the U.S. and is the exclusive distributor of Viragen’s natural interferon in South America and Hong Kong.
About Viragen, Inc.
Viragen is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include human natural alpha interferon, monoclonal antibodies, peptide drugs and therapeutic vaccines. Viragen’s strategy also includes the development of Avian Transgenic Technology for the large-scale, cost-effective manufacturing of its portfolio of protein-based drugs, as well as offering Contract Manufacturing for the entire biopharmaceutical industry.
Viragen is publicly traded on the American Stock Exchange (VRA). Viragen’s majority owned subsidiary, Viragen International, Inc., is publicly traded on the Over-The-Counter Bulletin Board (VGNI). Viragen’s key partners and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer Center, National Institutes of Health, Cancer Research UK, University of Nottingham (U.K.), University of Miami, America’s Blood Centers and the German Red Cross.
Viragen, Inc. Corporate Contacts
Douglas Calder, Director of Communications (Media & Investor Contact)
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
CJ Pharma Contact:
Jong H. Kim, Director, Global Commercial
Phone: (609) 897-0780; Fax: (609) 897-0725
E-mail: jhkok@cj.net
--------------------------------------------------
The foregoing press release contains forward-looking statements that can be identified by such terminology such as “expects”, “potential”, “suggests”, “may”, “will”, or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management’s expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the Company’s ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
--------------------------------------------------
Click HERE for previous press release.
PLANTATION, FLORIDA – May 22, 2003 – Viragen, Inc. (AMEX: “VRA”) and Viragen International, Inc. (OTC BB: “VGNI”) today announced that the Companies have entered into an exclusive distribution agreement with CJ Pharma, U.S. Pharmaceutical Division of CJ Corporation, and the CJ Hong Kong Ltd. subsidiary, as exclusive distributors of natural interferon in Hong Kong. Viragen’s human leukocyte-derived alpha interferon is currently approved in Hong Kong as a second-line therapy for the treatment of patients with Hairy Cell Leukemia (HCL) or Chronic Myelogenous Leukemia (CML) who did not respond to recombinant (synthetic) interferon regimens.
CJ Corporation (formerly Cheil Jedang) was established as the first manufacturing operation unit of the Samsung Group in 1953. Now a split-off of Samsung Group, the CJ Group recorded over $6 billion in revenues last year, conducting business with over 60 different countries through its thirty-two offices around the world.
“We are very pleased to build upon our relationship with a proven leader such as CJ Pharma,” stated Viragen’s Executive Vice President, Mel Rothberg. “We have been working very closely with CJ to commercialize our natural interferon in previously assigned territories in Latin America. Now we are expanding our work together to include the introduction of the drug into the Hong Kong market.”
CJ Pharma exclusively represents Viragen’s products in the following territories: Brazil, Chile, Uruguay, Peru, Costa Rica, Honduras, Nicaragua, Guatemala, Panama and Hong Kong. CJ Pharma is responsible for all costs associated with the regulatory approval process, including clinical trials if required, in each of the respective countries.
CJ Hong Kong’s General Manager, Mr. Jong Hwan Park, stated, “We are excited to attain the rights to distribute such a potent anti-viral product with Viragen’s multi-subtype human interferon. Our immediate priority is to expand the indications for which the product is currently approved to include a broad range of viral and malignant diseases and we are proceeding with the regulatory registration process.”
Dr. Andrew Gorman, Vice President, CJ Pharma (Princeton, NJ), stated “We believe that natural interferon represents a very attractive international market opportunity for us and our commitment to Viragen now extends from South America to Asia. Our foremost priority is to offer products that promote better health for everyone and this immune-enhancing drug offers that kind of promise in treating a variety of diseases.”
Backgrounder:
The majority of alpha interferons that are marketed are single-subtype recombinant interferons. Therapy resistance is not unusual with recombinant interferons with a significant percentage of patients failing to respond to standard therapy. In some instances, recombinant interferon is rejected by the patient’s immune system, usually caused by the formation of neutralizing antibodies which may lead to a loss of clinical efficacy. Also, many patients cannot tolerate the adverse side-effects sometimes associated with recombinant therapy. High doses of recombinant interferon may cause serious, even life-threatening side effects.
The Natural Choice
Viragen believes that in many cases, especially when higher dosages are required, its natural interferon appears to offer substantial advantages to recombinant interferon regimens:
Natural interferon is very similar to interferon secreted by the human immune system during a normal virus infection, significantly lowering the risk of the drug being rejected.
Natural interferon contains the multiple subtype composition that is characteristic of interferon produced by the human body. It is believed that this may result in a broader spectrum of anti-viral activity with each subtype perhaps showing a specific biological activity.
Natural interferon does not appear to cause the formation of neutralizing antibodies.
Natural interferon is significantly less immunogenic than recombinant interferon. It should be far better tolerated by patients with fewer side effects and thus allow for higher doses to be administered to maximize the benefits of the therapy.
About CJ Corporation:
CJ Corporation (formerly Cheil Jedang) was established as the first manufacturing operation unit of the Samsung Group in 1953. The CJ Group recorded over $6 billion in revenues last year, conducting business with over 60 different countries through its thirty-two offices around the world. CJ Pharma is the pharmaceutical division in the U.S. and is the exclusive distributor of Viragen’s natural interferon in South America and Hong Kong.
About Viragen, Inc.
Viragen is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include human natural alpha interferon, monoclonal antibodies, peptide drugs and therapeutic vaccines. Viragen’s strategy also includes the development of Avian Transgenic Technology for the large-scale, cost-effective manufacturing of its portfolio of protein-based drugs, as well as offering Contract Manufacturing for the entire biopharmaceutical industry.
Viragen is publicly traded on the American Stock Exchange (VRA). Viragen’s majority owned subsidiary, Viragen International, Inc., is publicly traded on the Over-The-Counter Bulletin Board (VGNI). Viragen’s key partners and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer Center, National Institutes of Health, Cancer Research UK, University of Nottingham (U.K.), University of Miami, America’s Blood Centers and the German Red Cross.
Viragen, Inc. Corporate Contacts
Douglas Calder, Director of Communications (Media & Investor Contact)
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
CJ Pharma Contact:
Jong H. Kim, Director, Global Commercial
Phone: (609) 897-0780; Fax: (609) 897-0725
E-mail: jhkok@cj.net
--------------------------------------------------
The foregoing press release contains forward-looking statements that can be identified by such terminology such as “expects”, “potential”, “suggests”, “may”, “will”, or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management’s expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the Company’s ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
--------------------------------------------------
Click HERE for previous press release.
ob ich dem satz wohl dieses mal folgen sollte ?
was meinst du mit "ob ich dem satz folgen sollte"? ICh habe gerade leider keine Zeit den rießen Text durchzulesen, kannst du mir kurz Info geben?
sollte es lieber mir geben.
You now von nichts kommt nichts
You now von nichts kommt nichts
die kurse sind schon super, hoffe das ihr die kurs schwachen tage mit käufen voll genutzt habt.
Na wenn das keine guten News sind! ;-)
Mexico Expands Approval For Viragen's Natural Interferon Allows Drug To Be Marketed For The Treatment Of Hepatitis C And Certain Cancers
PLANTATION, Fla., May 29, 2003 /PRNewswire-FirstCall via COMTEX/ -- Viragen,
Inc. (Amex: VRA) and its majority-owned subsidiary, Viragen International, Inc.
(OTC Bulletin Board: VGNI) today announced the approval of an application
submitted to Mexican regulatory authorities to expand the use of the natural
human alpha interferon drug, Multiferon(TM).
The Mexican regulatory authorities approved an application filed by Viragen's
strategic partner, Laboratorios Pisa, a leading Mexican pharmaceutical company,
to expand the use of Multiferon. This broadened approval extends use of the drug
to include the treatment of patients afflicted with any and all diseases in
which patients show an initial response to recombinant (synthetic) alpha
interferon followed by treatment failure, probably due to the formation of
neutralizing antibodies. Multiferon had previously been approved in Mexico for
the treatment of patients with hairy cell leukemia (HCL) or chronic myelogenous
leukemia (CML) who failed or relapsed to recombinant interferon regimens.
Multiferon is primarily being marketed for the treatment of hepatitis C and
certain cancers.
According to Viragen's Executive Vice President, Mr. Mel Rothberg, "This
expanded approval allows us to market Multiferon in Mexico for the treatment of
serious diseases such as hepatitis C and many cancers. Our Marketing team has
been working closely with Laboratorios Pisa in Mexico to identify those
physicians and patients who are most anxious to initiate a natural interferon
therapy."
"Based on the marketing initiatives that we are conducting with Viragen and the
initial positive feedback that we are receiving from physicians, we are now
anticipating higher sales figures for Multiferon than we had originally
expected," stated Pisa's General Director, Mr. Alfonso Alvarez. "Launching any
new pharmaceutical product can be a challenging endeavor, but we are very
excited about the growth prospects for natural interferon to treat a variety of
viral and malignant diseases."
Multiferon(TM) -- The Natural Choice:
Multiferon is a highly purified, multi-subtype, natural human alpha interferon
derived from human white blood cells and is approved in Sweden and Mexico for
the second-line treatment of any and all diseases in which patients show an
initial response to recombinant (synthetic) alpha interferon followed by
treatment failure, probably due to the formation of neutralizing antibodies.
Viragen's natural interferon is also approved for sale in the following
countries as a second-line therapy for the treatment of Hairy Cell Leukemia
(HCL) and Chronic Myelogenous Leukemia (CML): Czech Republic, Egypt, Hong Kong,
Indonesia, Myanmar, South Africa and Thailand. Work is ongoing to expand the
approved indications in these countries.
Regulatory approval processes are also underway in a number of other South
American, Middle East and Far East territories.
The Interferon Market:
The majority of alpha interferons that are marketed are single-subtype
recombinant interferons. Therapy resistance is not unusual with recombinant
interferons with a significant percentage of patients failing to respond to
standard therapy. In some instances, recombinant interferon is rejected by the
patient's immune system, usually caused by the formation of neutralizing
antibodies which may lead to a loss of clinical efficacy. Also, many patients
cannot tolerate the adverse side effects sometimes associated with recombinant
therapy. High doses of recombinant interferon may cause serious, even life-
threatening side effects. Viragen has observed that in many cases, especially
when higher dosages are required, its natural interferon appears to offer
substantial advantages to recombinant interferon regimens. The annual global
interferon market is estimated to exceed $3 billion.
About Viragen, Inc.
Viragen is a biotechnology company specializing in the research, development and
commercialization of natural and recombinant protein-based drugs designed to
treat a broad range of viral and malignant diseases. These protein-based drugs
include human natural alpha interferon, monoclonal antibodies, peptide drugs and
therapeutic vaccines. Viragen's strategy also includes the development of Avian
Transgenic Technology for the large-scale, cost-effective biomanufacturing of
human therapeutic protein drugs, such as monoclonal antibodies.
Viragen is publicly traded on the American Stock Exchange (VRA). Viragen's
majority owned subsidiary, Viragen International, Inc., is publicly traded on
the Over-The-Counter Bulletin Board (VGNI). Viragen's key partners and licensors
include: Roslin Institute, Memorial Sloan-Kettering Cancer Center, National
Institutes of Health, Cancer Research UK, University of Nottingham (U.K.),
University of Miami, America's Blood Centers and the German Red Cross.
For more information, please visit our Web site at: www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press release contains forward-looking statements that can be
identified by such terminology such as "expects", "potential", "suggests",
"may", "will", or similar expressions. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors that may cause the
actual results to be materially different from any future results, performance
or achievements expressed or implied by such statements. In particular,
management's expectations regarding future research, development and/or
commercial results could be affected by, among other things, uncertainties
relating to clinical trials and product development; availability of future
financing; unexpected regulatory delays or government regulation generally; the
Company's ability to obtain or maintain patent and other proprietary
intellectual property protection; and competition in general. Forward-looking
statements speak only as to the date they are made. The Company does not
undertake to update forward-looking statements to reflect circumstances or
events that occur after the date the forward-looking statements are made.
SOURCE Viragen, Inc.
CONTACT: Douglas Calder, Director of Communications, Viragen, Inc.,
+1-954-233-8746, or fax, +1-954-233-1414, or dcalder@viragen.com
/Photo: www.newscom.com/cgi-bin/prnh/ 20010426/HSTH018LOGO-b
AP Archive: photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
/Company News On-Call: www.prnewswire.com/gh/cnoc/comp/116574.html
URL: www.viragen.com
www.prnewswire.com
Mexico Expands Approval For Viragen's Natural Interferon Allows Drug To Be Marketed For The Treatment Of Hepatitis C And Certain Cancers
PLANTATION, Fla., May 29, 2003 /PRNewswire-FirstCall via COMTEX/ -- Viragen,
Inc. (Amex: VRA) and its majority-owned subsidiary, Viragen International, Inc.
(OTC Bulletin Board: VGNI) today announced the approval of an application
submitted to Mexican regulatory authorities to expand the use of the natural
human alpha interferon drug, Multiferon(TM).
The Mexican regulatory authorities approved an application filed by Viragen's
strategic partner, Laboratorios Pisa, a leading Mexican pharmaceutical company,
to expand the use of Multiferon. This broadened approval extends use of the drug
to include the treatment of patients afflicted with any and all diseases in
which patients show an initial response to recombinant (synthetic) alpha
interferon followed by treatment failure, probably due to the formation of
neutralizing antibodies. Multiferon had previously been approved in Mexico for
the treatment of patients with hairy cell leukemia (HCL) or chronic myelogenous
leukemia (CML) who failed or relapsed to recombinant interferon regimens.
Multiferon is primarily being marketed for the treatment of hepatitis C and
certain cancers.
According to Viragen's Executive Vice President, Mr. Mel Rothberg, "This
expanded approval allows us to market Multiferon in Mexico for the treatment of
serious diseases such as hepatitis C and many cancers. Our Marketing team has
been working closely with Laboratorios Pisa in Mexico to identify those
physicians and patients who are most anxious to initiate a natural interferon
therapy."
"Based on the marketing initiatives that we are conducting with Viragen and the
initial positive feedback that we are receiving from physicians, we are now
anticipating higher sales figures for Multiferon than we had originally
expected," stated Pisa's General Director, Mr. Alfonso Alvarez. "Launching any
new pharmaceutical product can be a challenging endeavor, but we are very
excited about the growth prospects for natural interferon to treat a variety of
viral and malignant diseases."
Multiferon(TM) -- The Natural Choice:
Multiferon is a highly purified, multi-subtype, natural human alpha interferon
derived from human white blood cells and is approved in Sweden and Mexico for
the second-line treatment of any and all diseases in which patients show an
initial response to recombinant (synthetic) alpha interferon followed by
treatment failure, probably due to the formation of neutralizing antibodies.
Viragen's natural interferon is also approved for sale in the following
countries as a second-line therapy for the treatment of Hairy Cell Leukemia
(HCL) and Chronic Myelogenous Leukemia (CML): Czech Republic, Egypt, Hong Kong,
Indonesia, Myanmar, South Africa and Thailand. Work is ongoing to expand the
approved indications in these countries.
Regulatory approval processes are also underway in a number of other South
American, Middle East and Far East territories.
The Interferon Market:
The majority of alpha interferons that are marketed are single-subtype
recombinant interferons. Therapy resistance is not unusual with recombinant
interferons with a significant percentage of patients failing to respond to
standard therapy. In some instances, recombinant interferon is rejected by the
patient's immune system, usually caused by the formation of neutralizing
antibodies which may lead to a loss of clinical efficacy. Also, many patients
cannot tolerate the adverse side effects sometimes associated with recombinant
therapy. High doses of recombinant interferon may cause serious, even life-
threatening side effects. Viragen has observed that in many cases, especially
when higher dosages are required, its natural interferon appears to offer
substantial advantages to recombinant interferon regimens. The annual global
interferon market is estimated to exceed $3 billion.
About Viragen, Inc.
Viragen is a biotechnology company specializing in the research, development and
commercialization of natural and recombinant protein-based drugs designed to
treat a broad range of viral and malignant diseases. These protein-based drugs
include human natural alpha interferon, monoclonal antibodies, peptide drugs and
therapeutic vaccines. Viragen's strategy also includes the development of Avian
Transgenic Technology for the large-scale, cost-effective biomanufacturing of
human therapeutic protein drugs, such as monoclonal antibodies.
Viragen is publicly traded on the American Stock Exchange (VRA). Viragen's
majority owned subsidiary, Viragen International, Inc., is publicly traded on
the Over-The-Counter Bulletin Board (VGNI). Viragen's key partners and licensors
include: Roslin Institute, Memorial Sloan-Kettering Cancer Center, National
Institutes of Health, Cancer Research UK, University of Nottingham (U.K.),
University of Miami, America's Blood Centers and the German Red Cross.
For more information, please visit our Web site at: www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press release contains forward-looking statements that can be
identified by such terminology such as "expects", "potential", "suggests",
"may", "will", or similar expressions. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors that may cause the
actual results to be materially different from any future results, performance
or achievements expressed or implied by such statements. In particular,
management's expectations regarding future research, development and/or
commercial results could be affected by, among other things, uncertainties
relating to clinical trials and product development; availability of future
financing; unexpected regulatory delays or government regulation generally; the
Company's ability to obtain or maintain patent and other proprietary
intellectual property protection; and competition in general. Forward-looking
statements speak only as to the date they are made. The Company does not
undertake to update forward-looking statements to reflect circumstances or
events that occur after the date the forward-looking statements are made.
SOURCE Viragen, Inc.
CONTACT: Douglas Calder, Director of Communications, Viragen, Inc.,
+1-954-233-8746, or fax, +1-954-233-1414, or dcalder@viragen.com
/Photo: www.newscom.com/cgi-bin/prnh/ 20010426/HSTH018LOGO-b
AP Archive: photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
/Company News On-Call: www.prnewswire.com/gh/cnoc/comp/116574.html
URL: www.viragen.com
www.prnewswire.com
Press Release Source: Viragen, Inc.
Viragen Continues To Meet American Stock Exchange Listing Criteria
Friday May 30, 1:27 pm ET
Company To Amend SEC Filing Which States Otherwise
PLANTATION, Fla., May 30 /PRNewswire/ -- Viragen, Inc. (Amex: VRA - News) today corrected erroneous information contained in a preliminary prospectus included in a Form S3 that the Company filed with the Securities and Exchange Commission (SEC) this morning.
The filing incorrectly states that, "We (Viragen) do not currently meet minimum bid price requirements of the American Stock Exchange (AMEX), and if we are delisted from the American Stock Exchange, the trading market for our common stock could be eliminated." Viragen currently meets AMEX maintenance criteria and is considered in good standing. The Company has no reason to believe that it is a candidate for possible delisting. The Company will immediately amend its Form S3 and file the corrected document with the SEC.
About Viragen, Inc.
Viragen is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon, monoclonal antibodies, peptide drugs and therapeutic vaccines. Viragen's strategy also includes the development of Avian Transgenic Technology for the large-scale, cost-effective manufacturing of its portfolio of protein-based drugs, as well as offering Contract Manufacturing for the entire biopharmaceutical industry.
Viragen is publicly traded on the American Stock Exchange (VRA). Viragen's majority owned subsidiary, Viragen International, Inc., is publicly traded on the Over-The-Counter Bulletin Board (VGNI). Viragen's key partners and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer Center, National Institutes of Health, Cancer Research UK, University of Nottingham (U.K.), University of Miami, America's Blood Centers and the German Red Cross.
For more information, please visit our Web site at: www.Viragen.com
Viragen Continues To Meet American Stock Exchange Listing Criteria
Friday May 30, 1:27 pm ET
Company To Amend SEC Filing Which States Otherwise
PLANTATION, Fla., May 30 /PRNewswire/ -- Viragen, Inc. (Amex: VRA - News) today corrected erroneous information contained in a preliminary prospectus included in a Form S3 that the Company filed with the Securities and Exchange Commission (SEC) this morning.
The filing incorrectly states that, "We (Viragen) do not currently meet minimum bid price requirements of the American Stock Exchange (AMEX), and if we are delisted from the American Stock Exchange, the trading market for our common stock could be eliminated." Viragen currently meets AMEX maintenance criteria and is considered in good standing. The Company has no reason to believe that it is a candidate for possible delisting. The Company will immediately amend its Form S3 and file the corrected document with the SEC.
About Viragen, Inc.
Viragen is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon, monoclonal antibodies, peptide drugs and therapeutic vaccines. Viragen's strategy also includes the development of Avian Transgenic Technology for the large-scale, cost-effective manufacturing of its portfolio of protein-based drugs, as well as offering Contract Manufacturing for the entire biopharmaceutical industry.
Viragen is publicly traded on the American Stock Exchange (VRA). Viragen's majority owned subsidiary, Viragen International, Inc., is publicly traded on the Over-The-Counter Bulletin Board (VGNI). Viragen's key partners and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer Center, National Institutes of Health, Cancer Research UK, University of Nottingham (U.K.), University of Miami, America's Blood Centers and the German Red Cross.
For more information, please visit our Web site at: www.Viragen.com
Viragen wird heute im Minus eröffnen, da sie in den USA auf 37 US-Cent steht. Mal schauen wie der Tagesverlauf aussieht...
mit Viragen los? Kaum noch Umsätze und ein rumgedümpel um die 30 Cent, das macht keinen Spaß...
Hi Börsenfan!
Bin erstmal raus, als sich im Orderbuch abzeichnete, dass die Handelsspanne sich zw. 0,36 und 0,38 festfährt. Der Moment ist erstmal weg! Habe dann in D zu 0,31 verkauft und
in Nanotechwerte umgeschichtet!
sonniger Gruss aus dem Süden
Bin erstmal raus, als sich im Orderbuch abzeichnete, dass die Handelsspanne sich zw. 0,36 und 0,38 festfährt. Der Moment ist erstmal weg! Habe dann in D zu 0,31 verkauft und
in Nanotechwerte umgeschichtet!
sonniger Gruss aus dem Süden
Hi,
Nanotechwerte? Welche denn genau?
Ebenfalls Gruss aus dem Süden (Stuttgart)
Nanotechwerte? Welche denn genau?
Ebenfalls Gruss aus dem Süden (Stuttgart)
Siehe Thread: http://www.ariva.de/board/165536/...backurl=index.m&a=all&677
Gruss aus FR vom Schwaben auf Abwegen ;-))
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem VERA BRADLEY INC Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 141 | wer möchte auf Geld verdien verzichten | TamerB | Tschoesu | 26.03.07 10:37 | ||
2 | 16 | Die Sensation 1000% und mehr..!!.kein problem | TamerB | TamerB | 25.01.05 09:50 | |
| 88 | Newsforum zu Viragen | Aktienbiene | Aktienbiene | 19.08.04 16:11 | ||
| 23 | Grippewelle in den USA: Viragen ein Zock ... | Zick-Zock | Rockraider | 17.12.03 14:52 | ||
| 17 | Bitte um Kauftip: Ich möchte | kalle4712 | Ninom3 | 23.09.03 16:43 |